Health Care Workload Impacts and Cost-Effectiveness of a Metabolomic Risk Score-based Health Check for Cardiometabolic Disease Prevention in Finland
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
We evaluated the impact on health care professionals’ workload and the long-term cost-effectiveness of a novel metabolomic risk score (MRS)-based health check compared with current practices in Finland’s working-age population.
Methods
A de novo individual-level microsimulation model was developed to estimate changes in labour time and cost-effectiveness of MRS-based health checks in detecting individuals at risk of cardiometabolic diseases (cardiovascular diseases; CVD or type 2 diabetes; T2D). The model used synthetic data on 256,372 Finnish individuals aged 50– 54 years without prior CVD or T2D. From a societal perspective, we assessed three scenarios: 1) replacing the standard health check with MRS-based health check, 2) replacing standard health check with MRS-based plus enhanced prevention, and 3) comparing enhanced standard check with MRS-based plus enhanced prevention. Outcomes included time required to identify at-risk individuals, incremental cost-effectiveness ratio per QALY gained, and cost-effectiveness acceptability curves.
Results
MRS-based health checks significantly reduced workload, saving 194,004 hours and 2902 hours for nurses and physicians over five years, respectively. The MRS-based approach was cost-saving across all scenarios, leading to discounted long-term savings ranging from €26 million to €298 million over the study period. In scenarios 1–2, it also improved QALYs, resulting in discounted gains ranging from 2017 to 8550 QALYs. In scenario 3, no QALY gains were observed, and minor losses occurred due to differences in baseline risk stratification.
Conclusions
MRS-based health checks in primary and occupational care can reduce workload and are a cost-saving strategy with health outcome benefits for identifying individuals at risk for cardiometabolic diseases.
Funding
This work was supported by Nightingale Health Plc.
